present in Gene: KRAS
present in Chromosome: 12
Position on Chromosome: 25225627
Alleles of this Variant: G/A
rs1057519725 in
KRAS gene and
Colorectal Neoplasms
PMID 20921462 2010 Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
PMID 21228335 2011 Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
PMID 19114683 2009 Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
PMID 19679400 2009 Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
PMID 20921465 2010 Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
PMID 16361624 2005 Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.
PMID 18316791 2008 Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
PMID 16618717 2006 KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.
rs1057519725 in
KRAS gene and
Thyroid Neoplasm
PMID 19773371 2009 Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.
PMID 19255327 2009 Phase II trial of sorafenib in metastatic thyroid cancer.
PMID 23406027 2013 Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.